First Hawaiian Bank Has $1.95 Million Holdings in Cencora, Inc. (NYSE:COR)

First Hawaiian Bank increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 29.4% during the second quarter, HoldingsChannel.com reports. The fund owned 8,633 shares of the company’s stock after buying an additional 1,963 shares during the quarter. First Hawaiian Bank’s holdings in Cencora were worth $1,945,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of COR. TD Asset Management Inc bought a new stake in Cencora in the first quarter valued at $95,313,000. LSV Asset Management bought a new stake in Cencora during the first quarter worth approximately $3,579,000. Cairn Investment Group Inc. purchased a new position in shares of Cencora during the 1st quarter worth about $2,294,000. Lake Street Advisors Group LLC bought a new stake in shares of Cencora during the first quarter worth $836,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in Cencora during the 1st quarter worth $1,862,000. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday. Citigroup lifted their price target on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. SVB Leerink restated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Robert W. Baird boosted their price objective on Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $249.63.

Insider Buying and Selling

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the sale, the insider now owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,899,112 shares of company stock valued at $408,654,376. 15.80% of the stock is owned by company insiders.

Cencora Stock Performance

COR stock traded down $6.29 on Monday, reaching $241.28. The company’s stock had a trading volume of 2,353,977 shares, compared to its average volume of 1,398,065. The firm has a fifty day moving average of $228.85 and a two-hundred day moving average of $231.36. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.53. The company has a market capitalization of $48.12 billion, a P/E ratio of 26.38, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $247.66.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.92 earnings per share. As a group, analysts predict that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 26th. Investors of record on Friday, August 9th will be given a dividend of $0.51 per share. The ex-dividend date is Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. Cencora’s dividend payout ratio is presently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.